What is CAR-T therapy, in simple terms
CAR-T (Chimeric Antigen Receptor T-cell) is a type of cell-based immunotherapy. The idea is not to suppress the tumor from outside but to make the patient's own immune system recognize it.
T-lymphocytes — cells of the immune system — are taken from the patient. In the laboratory, a special receptor (CAR) is built into them, "tuned" to a marker on tumor cells. The modified cells are then multiplied and returned to the body. After that, they find tumor cells by the set marker and destroy them. In essence, the immune system is given a "map of the target."
This is not chemotherapy or radiation. CAR-T is a "living drug": the medicine is the patient's own cells, reprogrammed for their disease.
Which conditions it's used for
CAR-T developed primarily in blood-cancer medicine. The main indications:
- B-cell lymphomas — including relapsed and refractory forms of large-cell lymphoma
- Acute lymphoblastic leukemias — especially in patients who did not respond to standard therapy
- Multiple myeloma — when the disease returns after previous treatment
The key phrase here is "relapsed and refractory" forms. CAR-T is often considered when classic lines of treatment — chemotherapy, targeted drugs — no longer respond. That is why, for many patients, it is not "one more option" but a real chance when few others remain.
Whether CAR-T fits a given case is decided only by the medical board (MDT) after reviewing the diagnosis, histology and history of prior treatment. It is not a method "for everyone" and not a replacement for other lines of therapy.
How treatment works — step by step
- Assessment of indicationsThe FFCH board reviews the documents and determines whether CAR-T is indicated in your specific case.
- Cell collection (apheresis)T-lymphocytes are separated from the patient's blood. The procedure resembles donating blood components.
- Laboratory manufacturingThe cells are genetically modified and multiplied. This usually takes several weeks.
- Patient preparationBefore infusion, preparatory therapy is given to "make room" for the new cells.
- Infusion and monitoringThe modified cells are returned to the body. After that the patient is closely monitored in hospital — a mandatory stage, because CAR-T has specific reactions that require medical supervision.
Why CAR-T at FFCH
CAR-T is a technically complex therapy that can only be carried out at clinics with the appropriate laboratory base and experience managing such patients. Foshan Fosun Chancheng Hospital is a top-category hospital in China Grade III Class A, and here CAR-T works alongside a multidisciplinary board and intensive-care support.
China is one of the world's leaders in the number of clinical programs in cell therapy, and access to CAR-T here is broader than in many other countries. For an international patient this means not only the technology itself but full support: medical interpreters, help with the visa, and documents to continue follow-up at home.